Form 4 for IMRX Immuneering Corp
Accepted 2022-03-24 00:00:00 ET · period of report 2022-03-23 · accession 0001415889-22-003324 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-24 | 2022-03-23 | IMRX | Zeskind Benjamin J. | Pres AND CEO, Dir, 10% | P - Purchase | $8.02 | +3,000 | 2.26M | +0.1% | +$24.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-03-23 | P | A | 3,000 | $8.02 | 2,257,352 | D | — | — | (F1) This transaction was executed in multiple trades through a broker-dealer at prices ranging from $7.92 to $8.10. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares acquired at each price. |